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Background and purpose: Fatigue is a common symptom in amyotrophic lateral
sclerosis (ALS). Although sleep disturbances are a candidate factor that may interfere
with fatigue in patients with ALS, the role of sleep-related abnormalities in deter-
mining fatigue in ALS is unknown.
Objective: To evaluate the frequency and determinants of fatigue in a group of 91
consecutive patients with ALS, with special attention to the relationship between
fatigue and sleep problems.
Methods: Measures included the Fatigue Severity Scale (FSS), Pittsburgh Sleep
Quality Index (PSQI), Epworth Sleepiness Scale (ESS), ALS Functional Rating Scale-
Revised (ALSFRS-R), and Beck Depression Inventory (BDI).
Results: The mean FSS score was 4.35 ± 1.1, and 48 patients with ALS (52.75%)
reported clinical signiﬁcant fatigue. FSS score correlated with ALSFRS-R score,
forced vital capacity, ESS, BDI, and global PSQI score. Patients with fatigue were
signiﬁcantly more disabled and more frequently reported diﬃculties staying asleep and
nocturnal complaints, such as nocturia and disturbing muscle cramps. After multi-
variate analysis, patients disability and nocturnal complaints were signiﬁcantly
associated with fatigue.
Conclusion: In this study, we demonstrated that fatigue, a troublesome and disabling
symptom in ALS, is associated with physical impairment and night-time complaints
(such as nocturia and muscle cramps), suggesting that treating sleep problems might
be useful in alleviating fatigue in these patients.
Introduction
Fatigue is a common symptom in amyotrophic lateral
sclerosis (ALS), aﬀecting 44–86% of patients with ALS
[1–3]. Fatigue has been deﬁned as an overwhelming
sense of tiredness, lack of energy, and feeling of
exhaustion [4]. It has an important impact on quality of
life in patients with ALS [1], and it has been indicated as
one of the reasons for shortening life in a Dutch study
[5]. Fatigue in ALS has been associated with disease
progression, age, site of ALS onset, ALS severity, and
depression [1–3].
The causes and mechanisms of fatigue in ALS are
multifactorial, including both central and peripheral
fatigue [4]. Psychological factors linked to disease evo-
lution and the physical obligates of daily life, respira-
tory impairment, and medications (including riluzole,
antispasticity, and antidepressants) could also play a
role [4].
Poor quality of sleep and excessive daytime somno-
lence could also contribute to fatigue in ALS. In pre-
vious studies, patients with ALS showed reduced total
sleep time, reduced sleep eﬃciency, and increased ap-
neas and hypopneas [6,7]. Moreover, patients with ALS
frequently reported night-time complaints such as
nocturia, muscle cramps, and restless legs syndrome [7–
9]. However, whether speciﬁc aspects of sleep aﬀect
fatigue in patients with ALS remains unknown [4].
Therefore, we decided to investigate the frequency
and determinants of fatigue in a large group of patients
with ALS, with special attention to the relationship
between fatigue and sleep problems.
Patients and methods
We collected detailed clinical data of 91 consecutive
patients with ALS during their routine visit to our ALS
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Center between February 2009 and June 2011. Patients
were diagnosed as deﬁnite or probable ALS according to
the El-Escorial WFN revised criteria [10].
All subjects underwent a standardized face-to-face
interview with a neurologist and expert in sleep medi-
cine (DLC), board certiﬁed by the Italian Association
of Sleep Medicine. The structured interview collected
data on sleep problems (yes or no type of answer).
Subjects had to specify whether they had: (i) persistent
initial insomnia (diﬃculty falling asleep within 30 min
or more); (ii) diﬃculties staying asleep (more than two
‡30-min nocturnal awakenings independently of the
need to use the bathroom, or undesirable early morning
awakening with inability to fall asleep again); (iii) un-
refreshing sleep (feeling tired and sleepy after waking in
the morning). Symptoms should have lasted at least for
1 month and had an impact on the subjects daily life.
Information was also sought on whether patients
snored, had nocturia, postural discomfort, pain, or
muscle cramps. Nocturnal complaints were deﬁned by
the presence of two or more of the above-mentioned
symptoms for at least three nights at week, and they
had to cause subjective discomfort.
In addition, the Pittsburgh Sleep Quality Index
(PSQI) was administered to all the study participants
[11]. A PSQI score > 5 was taken to indicate poor
sleep. Daytime somnolence was evaluated using the
Epworth Sleepiness Scale (ESS) [12]. Excessive daytime
sleepiness (EDS) was deﬁned by an ESS score ‡ 10.
Fatigue was evaluated by the Fatigue Severity Scale
(FSS) in which a score ‡ 4 indicates clinically signiﬁ-
cant fatigue [13]. The scale has been recently validated
in a large sample size of healthy subjects, who showed a
mean score of 3.0 ± 1.08 [14].
We also collected the following parameters for each
patient with ALS included in the study: date and area of
ALS onset, medical and drug history, forced vital
capacity (FVC), and use of nocturnal ventilation.
Severity of physical impairment was assessed by the
ALS Functional Rating Scale-Revised (ALSFRS-R)
[15]. Depression was evaluated using Beck Depression
Inventory (BDI) [16]. A score of >14 indicates
depression.
This study was approved by the institutional review
board of the University of Palermo. Written informed
consent was obtained from all participants.
Statistical analyses were carried out using SPSS 10.0
software (SPSS, Chicago, IL, USA). Continuous vari-
ables were compared with the Mann–Whitney U test,
and categorical variables were analyzed using the chi-
square test. Binary correlation was evaluated with
Spearmans correlation (q). Clinical and demographic
characteristics, and sleep-related complaints were also
compared in patients with and without fatigue (FSS ‡
or < 4) using a univariate statistical analysis. Results
were controlled using a stepwise multiple logistic
regression model. Odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs) were calculated. Because of mul-
tiple comparisons, a P value of < 0.01 (two-tailed) was
considered signiﬁcant.
Results
A total of 91 patients with ALS (36 women, 55 men;
mean age: 61.26 ± 10.1 years) were included in the
study. The site of ALS onset was bulbar in 24 patients
(26.4%). Patients had a mean duration of ALS symp-
toms of 24.9 ± 15.4 months, a mean ALSFRS-R score
of 33.85 ± 8.75, and a mean FVC of 75.1% ± 23.45.
Twelve patients used non-invasive ventilation. All but
six patients were taking riluzole. Mean BDI score was
10.5 ± 5.12, and 25 patients (27.5%) were depressed.
Sixteen patients (17.6%) were taking antispasticity or
antidepressants. No patients had overt dementia.
The mean global PSQI score of patients with ALS
was 7.0 ± 3.74. Fifty-two patients (57.14%) were
classiﬁed as poor sleepers (global PSQI score > 5). The
mean value of all components of PSQI is reported in
Table 1. The most common sleep problems reported by
patients with ALS were nocturia (62.6%), nocturnal
cramps (45%), diﬃculties turning in bed (38.5%), and
snoring (36.3%). Mean ESS score was 7.48 ± 2.54, and
22 patients (24.2%) had EDS.
The mean FSS score was 4.35 ± 1.1. Using the ac-
cepted cut-oﬀ of ‡4, 48 of 91 patients (52.75%) reported
clinical signiﬁcant fatigue. FSS score was signiﬁcantly
correlated with ALSFRS-R score (q = )0.51,
P < 0.001), FVC (q = )0.34, P = 0.001), ESS score
(q = 0.28, P = 0.007), BDI score (q = 0.31,
P = 0.003), and global PSQI score (q = 0.25,
P = 0.01).
Table 2 shows the clinical and demographic charac-
teristics of ALS patients with and without signiﬁcant
fatigue (FSS ‡4). Patients with fatigue were signiﬁcantly
more disabled (P < 0.001) and more frequently re-
ported diﬃculties staying asleep (P = 0.009) and noc-
turnal complaints (P = 0.002) than those without
fatigue. In the multivariate analysis – including ALS-
FRS-R, FVC, ESS, BDI, global PSQI, insomnia, and
night-time complaints as confounding factors – patients
disability (OR 0.91, 95% CI 0.86–0.97, P = 0.003) and
nocturnal complaints (OR 3.19, 95% CI 1.24–8.24,
P = 0.01) were signiﬁcant predictors of fatigue.
Discussion
In this cross-sectional study, we demonstrated that
fatigue, a troublesome and disabling symptom in ALS,
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is associated with sleep disturbances, in particular sleep
maintenance insomnia and night-time complaints.
Moreover, in common with previous ﬁndings [1–3], we
conﬁrmed that fatigue is a frequent problem in patients
with ALS, and in our study, more than half of patients
reported clinical signiﬁcant fatigue.
Both peripheral fatigue (muscle fatigability owing to
disorders of muscle and neuromuscular junction) and
central fatigue (the subjective sense of fatigue essentially
perceived at the level of the central nervous system)
could contribute to physical fatigue in ALS [4]. More-
over, incapacitating fatigue could be the result of a
potentially correctable sleep-related abnormality [4]. In
our study, sleep maintenance insomnia was signiﬁcantly
correlated with the presence of fatigue, and night-time
complaints strongly predicted clinical signiﬁcant fatigue
after physical disability had been controlled for. Our
results, then, strengthen the hypothesis that sleep dis-
turbances could be an important cause of fatigue in
patients with ALS. As nocturia and muscle cramps were
the most frequently reported night-time complaints, it is
possible that addressing these symptoms may improve
not only sleep but also fatigue in many patients. On the
contrary, initial insomnia and unrefreshing sleep were
not signiﬁcantly associated with the presence of fatigue.
These ﬁndings have implications for clinical man-
agement. As data on pharmacological agents relieving
fatigue in ALS are sparse, the clinician must use a
multimodality approach. It has been shown that psy-
chostimulant treatment (modaﬁnil) could be helpful, if
no treatable cause is identiﬁed [17]. Treatment of
associated depression or poor nutrition could also be
eﬀective. On the other hand, because there is some
evidence that ventilatory support could reduce fatigue
in other populations, non-invasive ventilation should be
considered in those patients with respiratory impair-
ment. In addition, muscle cramps should be aggres-
sively treated, and although at present there are
insuﬃcient data to support or refute any speciﬁc
intervention, gabapentin, vitamin E, and quinine could
be of use [18]. Nocturia can be treated with a number of
possible therapy options, depending on the etiology of
the condition, including anticholinergics (e.g. toltero-
dine, darifenacin, solifenacin), a-blockers/a-adrenergic
blockers (e.g. tamsulosin), or with desmopressin [19].
Finally, a variety of medications are available for use in
patients with insomnia, including benzodiazepines, the
non-benzodiazepine hypnotics (zolpidem, eszopiclone,
and zaleplon), antihistamines, and the sedating antide-
pressants (trazodone, amitriptyline, and mirtazapine).
Another interesting ﬁnding of the study was that we
documented a fair-to-moderate association between
fatigue and depression, daytime somnolence, and
respiratory function. These associations however were
no longer signiﬁcant when other contributing factors,
such as physical impairment, were accounted for,
showing that ALS severity was the most important
clinical predictor of fatigue in the patients studied.
Similarly, McElhiney et al. [3] also found an association
Table 2 Characteristics of patients with ALS with and without clinical signiﬁcant fatigue
Patients with fatigue (n = 48) Patients without fatigue (n = 43) P
Age, years 62.6 ± 8.66 59.77 ± 11.47 n.s.
Gender, M/F 29/19 26/17 n.s.
Duration of ALS symptoms, months 23.46 ± 14.78 26.51 ± 16.02 n.s.
Bulbar ALS onset 10 (20.8%) 14 (32.6%) n.s.
FVC, % of predicted 71.02 ± 21.87 79.65 ± 24.55 n.s.
ALSFRS-R score 30.65 ± 8.59 37. 24 ± 7.54 <0.001
ESS score 7.81 ± 2.74 7.12 ± 2.26 n.s.
BDI score 10.69 ± 4.83 10.28 ± 5.47 n.s.
Global PSQI score 7.36 ± 3.72 6.67 ± 3.75 n.s.
Difﬁculties falling asleep 17 (35.4%) 17 (39.5%) n.s.
Difﬁculties staying asleep 31 (64.6%) 16 (37.2%) 0.009
Unrefreshing sleep 18 (37.5%) 10 (23.3%) n.s.
Nocturnal complaints 28 (58.3%) 11 (25.6%) 0.002
ALS, amyotrophic lateral sclerosis; FVC, forced vital capacity; ALSFRS-R, ALS Functional Rating Scale-Revised; ESS, Epworth Sleepiness
Scale; BDI, Beck Depression Inventory; PSQI, Pittsburgh Sleep Quality Index.
Table 1 Components PSQI scores in patients with ALS
Components of PSQI ALS group, mean ± SD
Subjective sleep quality 0.93 ± 0.74
Sleep latency 1.32 ± 1.11
Sleep duration 1.14 ± 0.9
Habitual sleep efﬁciency 1.07 ± 0.92
Sleep disturbances 1.33 ± 0.61
Use of sleeping medication 0.32 ± 0.84
Daytime dysfunction 1.0 ± 0.86
Global PSQI score 7.0 ± 3.74
ALS, amyotrophic lateral sclerosis; PSQI, Pittsburgh Sleep Quality
Index.
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between clinical signiﬁcant fatigue and ALS severity.
They reported that the later stage of illness was asso-
ciated with higher rates of fatigue, and there was some
degree of overlap between symptoms of fatigue and
depression. In partial contrast, Ramirez et al. [2] re-
ported that fatigue was greater in the youngest patients
and worsened during follow-up, even if there was no
correlation between fatigue and ALSFRS-R score. Lou
et al. [1] also studied a small population of 25 patients
and found that fatigue had a signiﬁcant impact on
quality of life, but the severity of fatigue did not cor-
relate with physical impairment, measured using the
ALSFRS. Taken together, these studies show that fa-
tigue can have a great impact on patients with ALS,
although diﬀerences in the populations studied and in
the methodologies used might account for the dispari-
ties reported.
The main limitation of the present study is the lack of
objective measures of sleep quality, such as actigraphy
or polysomnography, to verify the accuracy of self-
report data, but we think it is extremely diﬃcult to
obtain these measures when examining large popula-
tions of patients. Moreover, the tools used in this study
are brief and easily administered, allowing a simple and
straightforward implementation in everyday clinical
practice.
Another limitation of the study is that we used a
unidimensional instrument to assess fatigue, so we
could not measure physical and mental fatigue inde-
pendently.
In conclusion, the results of our study further
strengthen the need for routine enquiries about fatigue
in ALS and suggest that questions about sleep and
nocturnal complaints should be included in the regular
review of patients with ALS, in particular those
reporting fatigue.
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